Method of treating a localized fibrotic disorder using an IL-33 antagonist

A method of treating a patient suffering from early disease stage Dupuytren's disease which comprises administering locally at the site of the early disease stage of Dupuytren's disease in the patient, an IL-33 antagonist which is an antibody that specifically binds to, and inhibits activation of, an IL-33 receptor or a binding fragment of such an antibody that specifically binds to and inhibits activation of an IL-33 receptor in an amount effective to downregulate expression of alpha-SMA, ST2 and COL1A1 in the patient's myofibroblasts so as to thereby treat the patient.